诺曲普利
抗焦虑药
氟奋乃静
焦虑
安慰剂
抑制剂
萧条(经济学)
心理学
医学
精神科
药理学
内科学
氟哌啶醇
阿米替林
病理
经济
多巴胺
替代医学
宏观经济学
作者
Sussex Clinical Trials Group,Sussex Clinical Trials Group
标识
DOI:10.1111/j.1600-0447.1985.tb02575.x
摘要
ABSTRACT– 233 patients attending their general practitioners for mixed anxiety/depressive states were treated on a double‐blind random allocation basis with one tablet to be taken three times daily, containing either 0.5 mg fluphenazine, 10 mg nortriptyline, a combination of 0.5 mg fluphenazine and 10 mg nortriptyline (Motival®), or placebo. After 7 and 28 days’ treatment, the combination product was found to be statistically superior to each of its active ingredients alone, as well as to placebo, with respect to anxiety, depression and non‐specific symptoms. Side effects were not a clinical problem and occurred with similar frequency in each treatment group. The superiority of Motival over each of its constituents is in keeping with previous studies showing advantages of the combination of fluphenazine and nortriptyline over anxiolytic and anti‐depressant drugs on their own.
科研通智能强力驱动
Strongly Powered by AbleSci AI